Brought to you by 
Eisai buys European rights to Prialt from Elan
15 Feb 2006
Executive Summary
Eisai Co. Ltd. bought the European marketing rights to Elan Corp. PLC's pain medicine Prialt (ziconotide) for $50mm up front plus $10mm at the earlier of two years or the drug's launch in key European markets.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Eisai buys European rights to Prialt from Elan
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice